It is time to bring back solvent-detergent plasma

Current Opinion in Hematology

Volumn 14, Issue 6, 2007, Pages 640-641

  Sandler, S Gerald ^a,b  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DETERGENT; SOLVENT;

BLOOD DONOR; EDITORIAL; HUMAN; MARKET; PHYSICIAN; PLASMA; PLASMA TRANSFUSION; PLASMA VOLUME; PRIORITY JOURNAL; UNITED STATES; VIRUS INFECTION; WEST NILE FLAVIVIRUS;

BLOOD COMPONENT TRANSFUSION; DETERGENTS; HUMANS; PLASMA; SOLVENTS;

EID: 34848864313     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3282e9a433     Document Type: Editorial

References (14)

1. Flamholz R, Jeon HR, Baron JM, et al. Study of three patients with thrombotic thrombocytopenic purpura exchanged with solvent/detergent-treated plasma: is its decreased protein S activity clinically related to their development of deep vein thrombosis? J Clin Apher 2000; 15:169-172.
2. Coingnard BP, Nguyen GT, Tokars JI, et al. A cluster of intraoperative deaths in a liver transplant center associated with the use of solvent/detergent plasma. California, 2000. Annual Meeting of the Society for Healthcare Epidemiology of America SHEA 2001, platform presentation No. 117.
3. De Jonge J, Groenland THN, Metselaar HU, et al. Fibrinolysis during liver transplantation is enhanced using solvent/detergent virus-inactivated plasma (ESDEP). Anesth Analg 2002; 94:1127-1131.
4. Yarranton H, Cohen H, Pavord SR, et al. Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura. Br J Haematol 2003; 121:778-785.
5. Kerr KI. Plasma's fatal flaw/new variety processed on LI connected to liver deaths. Newsday 2002, May 6:9-10.
6. Bryant BJ, Klein HG. Pathogen inactivation/the definitive safeguard for the blood supply. Arch Pathol Lab Med 2007; 131:719-733.
7. American Association of Blood Banks. Red Cross to discontinue providing PLAS+SD. In: AABB PulsePoints, no. 509. Bethesda, Maryland: American Association of Blood Banks; 2002.
8. Flesland O, Seghatchian J, Solheim BG. The Norwegian plasma fractionation project: a 12 year clinical and economic success story. Transfus Apher Sci 2003; 28:93-100.
9. Hellstern P. Solvent/detergent-treated plasma: composition, efficacy and safety. Curr Opin Hematol 2004; 11:346-350.
10. Kreil TR, Berting A, Kistner O, Kindermann J. West Nile virus and the safety of plasma derivatives: verification of high safety margins, and the validity of predictions based on model virus data. Transfusion 2003; 43:1023-1028.
11. Stainsby D, Jones H, Asher D, et al. Serious hazards of transfusion: a decade of hemovigilance in the UK. Transfus Med Rev 2006; 20:273-282.
12. Eder AF, Herron R, Strupp A, et al. Transfusion-related acute lung injury surveillance (2003-2005) and the potential impact of the selective use of plasma from male donors in the American Red Cross. Transfusion 2007;47:599-607.
13. Solheim BG, Seghatchian J. Update on pathogen reduction technology for therapeutic plasma: an overview. Transfus Apher Sci 2006; 35:83-90.
14. Thiéry G, Jacobs F, Bussel A, et al. Acute hyperphosphatemia after plasma exchange with S/D-treated plasma [letter]. Transfusion 2004; 44:947-948.